DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L, Li HT, Shereda R, Lu Q, Weisenberger DJ, O'Connell C, Machida K, An W, Lenz HJ, El-Khoueiry A, Jones PA, Liu M, Liang G.
Zhang L, et al.
Cancer Lett. 2022 Nov 1;548:215899. doi: 10.1016/j.canlet.2022.215899. Epub 2022 Sep 8.
Cancer Lett. 2022.
PMID: 36087682
Free PMC article.